Acquisition or disposition of SAB Biotherapeutics securities by Samuel Reich
| SABS Stock | USD 3.84 0.19 4.71% |
Slightly above 63% of SAB Biotherapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding SAB Biotherapeutics suggests that many traders are alarmed. SAB Biotherapeutics' investing sentiment can be driven by a variety of factors including economic data, SAB Biotherapeutics' earnings reports, geopolitical events, and overall market trends.
SAB |
Filed transaction by Sab Biotherapeutics Inc director. Acquisition or disposition under rule 16b-3
Read at macroaxis.com
SAB Biotherapeutics Fundamental Analysis
We analyze SAB Biotherapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of SAB Biotherapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of SAB Biotherapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Gross Profit
Gross Profit Comparative Analysis
SAB Biotherapeutics is currently under evaluation in gross profit category among its peers. Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.
SAB Biotherapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with SAB Biotherapeutics stock to make a market-neutral strategy. Peer analysis of SAB Biotherapeutics could also be used in its relative valuation, which is a method of valuing SAB Biotherapeutics by comparing valuation metrics with similar companies.
Peers
SAB Biotherapeutics Related Equities
| MNPR | Monopar Therapeutics | 3.64 | ||||
| VRAX | Virax Biolabs | 3.42 | ||||
| PCSA | Processa Pharmaceuticals | 1.16 | ||||
| CVKD | Cadrenal Therapeutics, | 1.69 | ||||
| QNRX | Quoin Pharmaceuticals | 6.06 | ||||
| CDIO | Cardio Diagnostics | 8.22 | ||||
| ANEB | Anebulo Pharmaceuticals | 10.43 | ||||
| UNCY | Unicycive Therapeutics | 10.81 | ||||
| THRD | Third Harmonic | 22.61 |
Additional Tools for SAB Stock Analysis
When running SAB Biotherapeutics' price analysis, check to measure SAB Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SAB Biotherapeutics is operating at the current time. Most of SAB Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of SAB Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SAB Biotherapeutics' price. Additionally, you may evaluate how the addition of SAB Biotherapeutics to your portfolios can decrease your overall portfolio volatility.